About this data
What it is
ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
Who files it
The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
How current
We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
Terms
ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
Worth knowing
A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
Not to be confused with
FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.

All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.

Studies updated per day, last 30 days

0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0
0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0

All industry-sponsored studies Sponsor matched to a public company

By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.

Latest clinical trial updates

Reset

Showing: ticker CELU · All recent updates

Studies by the date their record was last updated.

Latest clinical trial updates
UpdatedStudySponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).EnrolledPrimary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.Source
Jul 7, 2026PDA001 for the Treatment of Adults With Moderate-to-Severe Crohn's Disease
NCT01155362 · Crohn's Disease
Human Placenta-Derived Cells PDA001 Intravenous Infusion, V…
CELU
Celularity Incorporated
Phase 2Completed50Feb 2012Registry ↗
Jun 26, 2026Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19
NCT04365101 · Coronavirus, Coronavirus Infection
CYNK-001
CELU
Celularity Incorporated
Phase 1/2Terminated7Aug 30, 2021Registry ↗
Jun 12, 2026Efficacy and Safety of Intramuscular PDA-002 in Subjects With Diabetic Foot Ulcer With and Without…
NCT02264288 · Peripheral Arterial Disease, Diabetic Foot
PDA-002, Placebo
CELU
Celularity Incorporated
Phase 2Terminated159Feb 27, 2018Registry ↗
Jun 8, 2026CYNK-001 IV and IC in Combination With IL2 in Surgical Eligible Recurrent GBM With IDH-1 Wild Type
NCT05218408 · Astrocytoma, Grade IV, Glioblastoma
CYNK-001 systemic and Intra cavity administration
CELU
Celularity Incorporated
Phase 1/2Withdrawn0Oct 23, 2021Registry ↗
Jun 4, 2026Study of PDA-002 in Subjects With Peripheral Arterial Disease and Diabetic Foot Ulcers
NCT01859117 · Peripheral Arterial Disease, Diabetic Foot Ulcer
PDA-002
CELU
Celularity Incorporated
Phase 1Completed15Oct 1, 2016Registry ↗
Apr 29, 2026Hemodynamic Effects of Intramuscular PDA-002 in Subjects Who Have Diabetic Foot Ulcer With Peripher…
NCT02460081 · Diabetic Foot, Peripheral Arterial Disease
PDA-002, Placebo
CELU
Celularity Incorporated
Phase 2Withdrawn0Jan 2016Registry ↗
Dec 12, 2024CYNK-101 in Combination with Trastuzumab and Pembrolizumab in Patients with Locally Advanced Unrese…
NCT05207722 · Metastatic HER2 Positive Gastroesophageal Junction Cancer
CYNK-101, Pembrolizumab
CELU
Celularity Incorporated
Phase 1/2Terminated1Feb 15, 2024Registry ↗
Dec 12, 2024Natural Killer Cell (CYNK-001) Infusions in Adults with AML
NCT04310592 · Leukemia, Leukemia, Myeloid
CYNK-001
CELU
Celularity Incorporated
Phase 1Terminated27Jan 20, 2023Registry ↗
Feb 16, 2023Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma
NCT04309084 · Multiple Myeloma, Neoplasm, Plasma Cell
CYNK-001
CELU
Celularity Incorporated
Phase 1Unknown29Jan 31, 2023Registry ↗
Aug 10, 2022Natural Killer Cell (CYNK-001) IV Infusion or IT Administration in Adults With Recurrent GBM
NCT04489420 · Astrocytoma, Grade IV, Giant Cell Glioblastoma
CYNK001-IV, CYNK001-IT
CELU
Celularity Incorporated
Phase 1Terminated3Aug 10, 2021Registry ↗
Feb 2, 2022A Efficacy and Safety Study of Intramuscular Injection of Human Placenta-Derived Cells (PDA-002) in…
NCT02552277 · Diabetic Nephropathies, Peripheral Nervous System Diseases
PDA-002, Placebo
CELU
Celularity Incorporated
Phase 2Completed26Mar 7, 2017Registry ↗
Jul 22, 2020A Safety Study of Human Cord Blood Derived, Culture-expanded, Natural Killer Cell (PNK-007) Infusio…
NCT02955550 · Multiple Myeloma
rhIL-2, PNK-007
CELU
Celularity Incorporated
Phase 1Completed15Jul 10, 2018Registry ↗
Jul 22, 2020A Safety Study of Human Cord Blood Derived, Culture Expanded Natural Killer Cell (PNK-007) Infusion…
NCT02781467 · Leukemia, Myeloid, Acute
PNK-007, Cyclophosphamide
CELU
Celularity Incorporated
Phase 1Terminated10Dec 7, 2017Registry ↗
Jul 22, 2020Study of Human Placenta-derived Cells (PDA001) to Evaluate the Safety and Effectiveness for Patient…
NCT01261403 · Rheumatoid Arthritis
PDA001, Vehicle Controlled Placebo
CELU
Celularity Incorporated
Phase 2Terminated26Feb 2012Registry ↗
Mar 1, 2018A Randomized, Double-Blind, Placebo-Controlled Dose-Escalation Study to Determine the Safety and Ef…
NCT01769755 · Crohns Disease
PDA001, Vehicle Controlled Placebo
CELU
Celularity Incorporated
Phase 1Completed14Nov 2014Registry ↗
Mar 1, 2018Safety of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults…
NCT01440192 · Stage 2 Pulmonary Sarcoidosis, Stage 3 Pulmonary Sarcoidosis
PDA001 (cenplacel-L)
CELU
Celularity Incorporated
Phase 1Terminated4Feb 2014Registry ↗
Mar 1, 2018Study of Human Placenta-derived Cells (PDA001) to Evaluate the Safety and Effectiveness for Patient…
NCT01310114 · Stroke, Acute, Middle Cerebral Artery Stroke
Human Placenta-Derived Cells PDA001- (cenplacel-L), Placebo
CELU
Celularity Incorporated
Phase 2Terminated44Mar 2013Registry ↗

17 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 9:13 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances